Baxter Files for Pediatric Indication of RIXUBIS [Coagulation Factor IX (Recombinant)] Treatment for Hemophilia B in the United States

16-12-2013 Business Wire HealthComments (0)

BaxterPharmaceutical

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter has submitted an application to the U.S. FDA for a pediatric indication for RIXUBIS to treat hemophilia B, based on study results presented during the ASH Annual Meeting.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top